- Home
- PCB vs PRQR Comparison
PCB vs PRQR Comparison
Compare PCB & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCB
- PRQR
- Stock Information
- Founded
- PCB 2003
- PRQR 2012
- Country
- PCB United States
- PRQR Netherlands
- Employees
- PCB N/A
- PRQR N/A
- Industry
- PCB Major Banks
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- PCB Finance
- PRQR Health Care
- Exchange
- PCB Nasdaq
- PRQR Nasdaq
- Market Cap
- PCB 285.3M
- PRQR 309.5M
- IPO Year
- PCB N/A
- PRQR 2014
- Fundamental
- Price
- PCB $20.55
- PRQR $2.68
- Analyst Decision
- PCB Hold
- PRQR Strong Buy
- Analyst Count
- PCB 2
- PRQR 5
- Target Price
- PCB $22.00
- PRQR $7.60
- AVG Volume (30 Days)
- PCB 29.0K
- PRQR 605.4K
- Earning Date
- PCB 01-23-2025
- PRQR 11-07-2024
- Dividend Yield
- PCB 3.50%
- PRQR N/A
- EPS Growth
- PCB N/A
- PRQR N/A
- EPS
- PCB 1.68
- PRQR N/A
- Revenue
- PCB $94,833,000.00
- PRQR $20,506,357.00
- Revenue This Year
- PCB N/A
- PRQR $235.11
- Revenue Next Year
- PCB $10.34
- PRQR N/A
- P/E Ratio
- PCB $12.24
- PRQR N/A
- Revenue Growth
- PCB N/A
- PRQR 306.68
- 52 Week Low
- PCB $14.50
- PRQR $1.61
- 52 Week High
- PCB $22.20
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- PCB 46.69
- PRQR 38.34
- Support Level
- PCB $19.09
- PRQR $2.48
- Resistance Level
- PCB $20.63
- PRQR $2.83
- Average True Range (ATR)
- PCB 0.64
- PRQR 0.28
- MACD
- PCB -0.21
- PRQR -0.06
- Stochastic Oscillator
- PCB 46.95
- PRQR 28.78
About PCB PCB Bancorp
PCB Bancorp is a bank holding company, which engages in the provision of consumer and commercial banking services. It provides Personal, Business, and Loan services, which provide banking, lending, and digital, tools, home loans, and others. Also, it offers a broad range of loans, deposits, and other products and services predominantly to small and middle-market businesses and individuals.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.